Cargando…

High efficacy of BGD (bendamustine, gemcitabine, and dexamethasone) in relapsed/refractory Hodgkin Lymphoma

The optimal salvage therapy in relapsed/refractory Hodgkin lymphoma (R/R HL) has not been defined so far. The goal of this multicenter retrospective study was to evaluate efficacy and safety of BGD (bendamustine, gemcitabine, dexamethasone) as a second or subsequent line of therapy in classical R/R...

Descripción completa

Detalles Bibliográficos
Autores principales:	Swoboda, Ryszard, Giebel, Sebastian, Knopińska-Posłuszny, Wanda, Chmielowska, Ewa, Drozd-Sokołowska, Joanna, Paszkiewicz-Kozik, Ewa, Kulikowski, Waldemar, Taszner, Michał, Mendrek, Włodzimierz, Najda, Jacek, Czerw, Tomasz, Olszewska-Szopa, Magdalena, Czyż, Anna, Giza, Agnieszka, Spychałowicz, Wojciech, Subocz, Edyta, Szwedyk, Paweł, Krzywon, Aleksandra, Wilk, Agata, Zaucha, Jan Maciej
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2021
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8195914/ https://www.ncbi.nlm.nih.gov/pubmed/33625572 http://dx.doi.org/10.1007/s00277-021-04448-5

Ejemplares similares

Correction to: High efficacy of BGD (bendamustine, gemcitabine, and dexamethasone) in relapsed/refractory Hodgkin lymphoma
por: Swoboda, Ryszard, et al.
Publicado: (2021)

A survey across orbital lymphoma in Poland: Multicenter retrospective study of polish lymphoma research group (PLRG)
por: Kalicińska, Elżbieta, et al.
Publicado: (2022)

P017: The role of baseline bulk and dissemination measures as predictors of progression in advanced Hodgkin lymphoma
por: Taszner, Michal, et al.
Publicado: (2022)

Comparable safety profile of BeEAM (bendamustine, etoposide, cytarabine, melphalan) and BEAM (carmustine, etoposide, cytarabine, melphalan) as conditioning before autologous haematopoietic cell transplantation
por: Frankiewicz, Andrzej, et al.
Publicado: (2018)

Type 2 diabetes mellitus compromises the survival of diffuse large B-cell lymphoma patients treated with (R)-CHOP – the PLRG report
por: Drozd-Sokolowska, Joanna, et al.
Publicado: (2020)

BGD: A Database of Bat Genomes
por: Fang, Jianfei, et al.
Publicado: (2015)

Ofatumumab with iphosphamide, etoposide and cytarabine for patients with transplantation‐ineligible relapsed and refractory diffuse large B‐cell lymphoma
por: Paszkiewicz‐Kozik, Ewa, et al.
Publicado: (2022)

First‐line R‐CVP versus R‐CHOP induction immunochemotherapy for indolent lymphoma with rituximab maintenance. A multicentre, phase III randomized study by the Polish Lymphoma Research Group PLRG4
por: Walewski, Jan, et al.
Publicado: (2019)

The impact of blood donation on bone marrow harvest efficiency
por: Mitrus, Iwona, et al.
Publicado: (2022)

Spatial separation of the cyanogenic β-glucosidase ZfBGD2 and cyanogenic glucosides in the haemolymph of Zygaena larvae facilitates cyanide release
por: Pentzold, Stefan, et al.
Publicado: (2017)

Randomized phase 2 study of otlertuzumab and bendamustine versus bendamustine in patients with relapsed chronic lymphocytic leukaemia
por: Robak, Tadeusz, et al.
Publicado: (2016)

Bendamustine-Based Regimens as Salvage Therapy in Refractory/Relapsed Multiple Myeloma Patients: A Retrospective Real-Life Analysis by the Polish Myeloma Group
por: Grzasko, Norbert, et al.
Publicado: (2021)

Follow-up of patients with mycosis fungoides after interferon α2b treatment failure
por: Chmielowska, Ewa, et al.
Publicado: (2015)

PB1999: TOBACCO SMOKING IN MDS PATIENTS – ANALYSIS FROM THE MDS PALG REGISTRY
por: Machowicz, Rafal, et al.
Publicado: (2023)

Nivolumab in two cases of refractory mycosis fungoides erythroderma
por: Chmielowska, Ewa
Publicado: (2021)

The Real-World Evidence on the Fragility and Its Impact on the Choice of Treatment Regimen in Newly Diagnosed Patients with Multiple Myeloma over 75 Years of Age
por: Tyczyńska, Agata, et al.
Publicado: (2023)

Immunological reactions induced by bendamustine
por: Sanchez-Gonzalez, Maria-Jose, et al.
Publicado: (2014)

The use of Yttrium-90 Ibritumomab Tiuxetan ((90)Y-IT) as a consolidation therapy in high-risk patients with diffuse large B-cell lymphoma ineligible for autologous stem-cell transplantation
por: Jurczak, Wojciech, et al.
Publicado: (2015)

MRD response in relapsed/refractory FL after obinutuzumab plus bendamustine or bendamustine alone in the GADOLIN trial
por: Pott, Christiane, et al.
Publicado: (2019)

T021: Radiation-Free Therapy as the INitial treatment of Good-prognosis early non-bulky Hodgkin lymphoma, defined by a low Metabolic Tumor Volume and a negative PET-2 - RAFTING Trial.
por: Gallamini, Andrea, et al.
Publicado: (2022)

Bendamustine in the treatment of non-Hodgkin’s lymphomas
por: Hagemeister, Fredrick, et al.
Publicado: (2009)

Bendamustine Associated with Irreversible Ascending Paralysis
por: Alhafez, Ashraf, et al.
Publicado: (2013)

Lichenoid drug eruption associated with Bendamustine
por: Kusano, Y, et al.
Publicado: (2016)

Determination of Bendamustine in Human Plasma and Urine by LC-FL Methods: Application in a Drug Monitoring
por: Plenis, Alina, et al.
Publicado: (2016)

P1103: OBINUTUZUMAB INDUCTION AND MAINTENANCE IN PATIENTS WITH RELAPSED/REFRACTORY WALDENSTRÖM MACROGLOBULINAEMIA
por: Wróbel, Tomasz, et al.
Publicado: (2023)

Electrically and Thermally Conductive Low Density Polyethylene-Based Nanocomposites Reinforced by MWCNT or Hybrid MWCNT/Graphene Nanoplatelets with Improved Thermo-Oxidative Stability
por: Paszkiewicz, Sandra, et al.
Publicado: (2018)

Enhanced Functional Properties of Low-Density Polyethylene Nanocomposites Containing Hybrid Fillers of Multi-Walled Carbon Nanotubes and Nano Carbon Black
por: Paszkiewicz, Sandra, et al.
Publicado: (2020)

Bendamustine in patients with relapsed or refractory multiple myeloma
por: Michael, M, et al.
Publicado: (2010)

Role of bendamustine in the treatment of chronic lymphocytic leukemia
por: Jamshed, Saad, et al.
Publicado: (2009)

Pharmacokinetic and pharmacodynamic profile of bendamustine and its metabolites
por: Darwish, Mona, et al.
Publicado: (2015)

Herpetic esophagitis following bendamustine-containing regimen
por: Yamane, Hiromichi, et al.
Publicado: (2016)

Inhibition of STAT3 by Anticancer Drug Bendamustine
por: Iwamoto, Kazunori, et al.
Publicado: (2017)

Immunomodulatory Effects of Bendamustine in Hematopoietic Cell Transplantation
por: Stokes, Jessica, et al.
Publicado: (2021)

Reduced bendamustine for elderly patients with follicular lymphoma
por: Masamoto, Yosuke, et al.
Publicado: (2021)

Bendamustine and pneumocystis pneumonia: A systematic review
por: Hakamifard, Atousa, et al.
Publicado: (2022)

Rituximab and Bendamustine (BR) Compared with Rituximab, Bendamustine, and Cytarabine (R-BAC) in Previously Untreated Elderly Patients with Mantle Cell Lymphoma
por: Bega, Giulia, et al.
Publicado: (2021)

In Silico Designed Gain-of-Function Variants of Complement C2 Support Cytocidal Activity of Anticancer Monoclonal Antibodies
por: Urban, Aleksandra, et al.
Publicado: (2022)

Venetoclax plus bendamustine-rituximab or bendamustine-obinutuzumab in chronic lymphocytic leukemia: final results of a phase Ib study (GO28440)
por: Stilgenbauer, Stephan, et al.
Publicado: (2020)

New record of the fish leech Piscicola pojmanskae (Annelida: Hirudinida: Piscicolidae) - DNA barcoding and phylogeny
por: Cichocka, Joanna M., et al.
Publicado: (2018)

The role of bendamustine in the treatment of indolent non-Hodgkin lymphoma
por: Aldoss, Ibrahim T, et al.
Publicado: (2009)

Cannot write session to /tmp/vufind_sessions/sess_muj6o94j19lg4hkek7mdi6r4em